EyePoint, Inc. has announced a major strategic shift, reducing its workforce by approximately 53% as part of a plan to focus resources on its diabetic macular edema (DME) program. This decision comes after a review of the topline results from its pivotal Phase 3 clinical trial evaluating DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD). The company expects to incur around $9 million in charges related to employee separation benefits as it implements this prioritization.
This move is significant for EyePoint as it seeks to streamline operations and concentrate on its late-stage programs. The company has indicated that the majority of the workforce reduction will occur in the fourth quarter of 2026 and be completed by the first half of 2027. The decision reflects the current challenges faced by companies in the laboratory analytical instruments industry, where adapting to market demands is crucial for survival.
Background
EyePoint, Inc. is a company focused on developing innovative therapeutics for eye diseases. It operates under the Standard Industrial Classification (SIC) code 3826, which pertains to laboratory analytical instruments. EyePoint trades on the Nasdaq under the ticker symbol EYPT. The company has undergone several name changes in its history, including its previous name, EyePoint Pharmaceuticals, Inc., which it adopted in March 2018.
What the Filing Says
According to the recent SEC filing dated October 19, 2026, EyePoint's board approved a strategic prioritization plan designed to reduce operating expenses. The filing states, "The Prioritization includes a plan to conclude the pivotal Phase 3 wet AMD clinical trials early and reduce the Company’s workforce by approximately 53%." The company estimates that it will incur aggregate charges of approximately $9 million related to this workforce reduction.
Impact
The workforce reduction is expected to significantly affect EyePoint's employees, with the majority of layoffs anticipated in the upcoming months. Additionally, the decision may influence the company's operational capabilities and its ability to compete in the laboratory analytical instruments sector. This strategic shift may prompt competitors to reevaluate their own operational strategies in light of EyePoint's new focus.
What's Next
The filing does not specify what happens next beyond the workforce reduction and the shift in focus to the DME program. EyePoint will likely continue to monitor its financial position and operational performance as it implements these changes.